MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD).
- Mechanism
- Curator reviewed
MN-305 is a potent and highly-selective full agonist at the serotonin 5-HT1A receptor under development by MediciNova both for the treatment of insomnia, as well as for anxiety disorders such as Generalized Anxiety Disorder (GAD). MN-305 has been evaluated in an extensive preclinical toxicology program which showed no evidence of inducing genetic mutations, immune response or cancer. MN-305 has also proved to be consistently well-tolerated in clinical safety, efficacy and pharmacokinetic studies in over 1,200 subjects.
- Primary indication
- Investigated for use/treatment in anxiety disorders, depression, insomnia, and neurologic disorders.Curator reviewed
- Formula / weight
- C19H22ClNO5 · 379.835 g/mol (avg)
- Code names
- MN-305
Resolves to
GGNCUSDIUUCNKE-RSAXXLAASA-NSMILESCl.C(CNC[C@H]1COC2=CC=CC=C2O1)COC1=CC2=C(OCO2)C=C1What you can answer from here — as of June 15, 2026
Which drugs share a target with Osemozotan, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account